Shire bags US approval for constipation drug Motegrity

Bausch Health (formerly Valeant) has just launched a bid for the company on the premise that it will be able to kick start sales of Trulance, Synergy’s only-approved product,

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in

Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response

UK, Germany back routine use of J&J’s Tremfya

Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]